NONMEM Users Network Archive

Hosted by Cognigen

RE: ASCO and pharmacometrics

From: Gobburu, Joga <jgobburu>
Date: Thu, 7 Apr 2016 17:59:42 +0000

Dear Naoto-san et al,

Has it ever occurred to us that we might have to change first, not others!

Not having reviewed the abstract, I cannot comment on the potential reasons why the abstract was not accepted at ASCO. Somehow – that event is translated in to ‘Oh! ASCO doesn’t like pharmacometrics’ – it is a stretch. On the same token, are we inviting with open arms ASCO scientists to our clinical pharmacology meetings? This is a two-way street.
I don’t deny that there is room for change on both sides – but it has to be both sides. Most pharmacometricians talk in PREDPP, and not in drug development terms. We need to take a long term view – 10 or 20 years ago we might not have considered submitting our work to clinical meetings. Today we are – which is progress. I see more and more clinical pharmacology topics discussed at clinical meetings. So picture is not so gloomy.

How do we catalyze our presence at clinical meetings?

a. We first need to understand the agenda of those meetings and find mutually interesting topics.

b. We need to build relationships with key leadership of these clinical organizations. These clinical meetings are sponsored to a great extent by companies. Well our folks in the companies can lobby to create sessions of interest to both groups.

c. We should be the change we want to see. Invite key leaders from the clinical conference to ours.

d. We need to train ourselves better in drug development and communicating with inter-disciplinary scientists; and not stuck on the methodology.

Joga Gobburu
Professor, University of Maryland
Center for Translational Medicine

From: owner-nmusers ilto:owner-nmusers
Sent: Thursday, April 7, 2016 11:36 AM
To: nmusers <nmusers
Subject: Re: [NMusers] ASCO and pharmacometrics

I agree with Phil. I have presented recently at two large endocrine meetings, one in the US, one in Europe. In both cases, I took complicated PK/PD models and kept it simple, emphasizing how the models could / would be used in clinical development and clinical practice. The response at both meetings was excellent — lots of people expressing interest in the models (and, interestingly, two of the competitors to the company for which I was consulting tried to enlist my consulting help).

And, I disagree with Nick’s comment yesterday. Perhaps oncology clinicians are concerned about commas (I cannot speak to that issue) but I truly doubt Nick’s claim that they don’t care about science — the advances in oncology in recent years have been remarkable.

Dennis Fisher MD
P < (The "P Less Than" Company)
Phone: 1-866-PLessThan (1-866-753-7784)
Fax: 1-866-PLessThan (1-866-753-7784)<>

On Apr 7, 2016, at 7:49 AM, Lowe, Phil <phil.lowe

I would echo Pascal’s point. Getting pharmacometric work into large clinical conferences is not straightforward. It can be done (see link) but note where I was in the author list as the sole modeller. It helps to work closely with the clinicians on the messaging. That said, it was fun at the meeting, explaining the data and model curves to clinicians with them asking how such knowledge could impact their patients. An eye-opener. Keep trying Naoto!

All the best, Phil

Philip J Lowe PhD
Executive Director Pharmacometrics Scientist
Novartis Pharma AG, WSJ-027.6.25 or WSJ-386.12.48.46
4056 Basel, Switzerland
Phone: +41 61 324 4676
phil.lowe hil.lowe

From: owner-nmusers com<mailto:owner-nmusers
Sent: 06 April 2016 10:39
To: Naoto Hayashi; jgrevel com<mailto:jgrevel
Cc: nmusers
Subject: RE: [NMusers] ASCO and pharmacometrics

Dear Naoto,

In the past, Rene Bruno got one poster accepted with discussion at ASCO. He is our ”champion” !

I got one accepted on model for Exp-Tumor Size – OS at European Cancer Congress 2013 . But I can tell you that a medical writer rewrote it entirely and it took 1 month to get it reviewed and corrected by clinicians challenging every comma and p-value.

To give you an idea of the respective size of the meetings: ACOP N=500, PAGE N>600, ECC N> 10,000, ASCO N>20,000.

So the advice I would give, is just improve the quality and readability of our abstract and it will make it. By readability, I mean show it to an oncologist clinician. If he does not understand, rewrite it with the help of a medical writer …

With best regards / Mit freundlichen Grüßen / Cordialement


Received on Thu Apr 07 2016 - 13:59:42 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: